BridgeMD
Tests treatment safety and results for Type 1 Diabetes
Official title Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2
ClinicalTrials.gov ID: NCT07097818
What this study is testing
- What it's testing
- The GLITTER Study 2 is a cluster randomized trial that will evaluate the impact of comprehensive and intensive management, comprising a team, technology, education, and peer resources, on metabolic control and psychological outcomes in patients with type 1 diabetes.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 6 and older
You may be able to join if
- Eligibility criteria for study hospitals:
- Members of the China Diabetes Type 1 Study (CD1S).
- Experience in type 1 diabetes management: treat more than 50 T1D patients per year and have held camp activities at least once.
- Have type 1 diabetes educators. Eligibility criteria of study participants:
- Diagnosis of Type 1 Diabetes.
You likely can't join if
- of study participants:
- Patients who plan to receive diabetes treatment at other hospitals.
- Patients who have used an automated insulin delivery system or sensor-augmented pump within 3 months prior to screening.
- Patients who refuse to use continuous glucose monitoring or insulin pumps, or refuse data upload and remote monitoring.
- Patients with severe cardiovascular, cerebrovascular, hepatic, or renal diseases; uncontrolled systemic diseases, thyroid diseases; autoimmune...
- Patients diagnosed with hematologic or bleeding disorders.
See the full eligibility criteria
- Eligibility criteria for study hospitals:
- Members of the China Diabetes Type 1 Study (CD1S).
- Experience in type 1 diabetes management: treat more than 50 T1D patients per year and have held camp activities at least once.
- Have type 1 diabetes educators. Eligibility criteria of study participants:
- Diagnosis of Type 1 Diabetes.
- Age ≥6 years, regardless of gender.
- Duration of disease \>3 months.
- Planned to attend follow-up visits at this hospital within the next year.
- Possess sufficient cognitive ability to operate all study-related devices.
- Willing to use continuous glucose monitoring and insulin pumps, upload data, and participate in remote monitoring.
- Willing to attend structured education sessions and camp activities on time (for the intervention group only).
- Willing and able to adhere to the study protocol.
- Willing to sign the informed consent form.
- of study participants:
- Patients who plan to receive diabetes treatment at other hospitals.
- Patients who have used an automated insulin delivery system or sensor-augmented pump within 3 months prior to screening.
- Patients who refuse to use continuous glucose monitoring or insulin pumps, or refuse data upload and remote monitoring.
- Patients with severe cardiovascular, cerebrovascular, hepatic, or renal diseases; uncontrolled systemic diseases, thyroid diseases; autoimmune diseases; or malignancies.
- Patients diagnosed with hematologic or bleeding disorders.
- Patients who have received red blood cell transfusions or erythropoiesis-stimulating agents within 3 months prior to screening.
- Patients who have used any oral, injectable, or intravenous corticosteroids within 8 weeks prior to screening, or who plan to use corticosteroids during the trial.
- Patients with severe skin diseases that may affect the application sites of continuous glucose monitoring or insulin pump patches.
- Patients with auditory or visual impairments.
- Patients with alcohol or drug abuse.
- Patients who plan to receive blood transfusions during the study period.
- Patients who plan to undergo elective surgery requiring general anesthesia or dialysis during the study period.
- Pregnant women, women planning to become pregnant within 1 year of the study, or women who are breastfeeding.
- Patients who are currently participating in or have participated in other drug or device trials within the last 2 weeks.
- Patients who, in the investigator's opinion, are not suitable for participation in this clinical trial, such as those with a history of vision impairment, eating disorders, celiac disease, etc.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
- Quanzhou, Fujian, China
- Shenzhen, Guangdong, China
- Tangshan, Hebei, China
- Luoyang, Henan, China
- Wuhan, Hubei, China
- Changsha, Hunan, China
- Shenyang, Liaoning, China
- Chengdu, Sichuan, China
- Hangzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 6 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China; Quanzhou, Fujian, China; Shenzhen, Guangdong, China; Tangshan, Hebei, China; Luoyang, Henan, China; Wuhan, Hubei, China and 4 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.